Clinical trial Recruiting at 1 site Early Phase 1 Interventional Ages 18 to 90

Low Intensity Focused Ultrasound for Essential Tremor in Adults

Official title: Open Label Study for the Use of Low Intensity Focused Ultrasound for Essential Tremor

Run by University of California, Los Angeles · NCT07599592 · Data updated 2026-11-12

This early-stage, open-label study tests whether repeated low-intensity focused ultrasound can safely and briefly modulate tremor in people with essential tremor.

Quick facts

PhaseEarly Phase 1
Study typeInterventional
Ages18 Years to 90 Years
SexAll
Enrollment20 (estimated)
SponsorUniversity of California, Los Angeles
Academic / other
Locations1 site (Los Angeles, California)
StatusRecruiting
StartedMay 1, 2026
Main results expectedDecember 31, 2026
Study endsJune 1, 2027
Registry record updatedMay 20, 2026
Trial IDNCT07599592 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with a clinical diagnosis of essential tremor, tremor as the primary symptom for at least three years, and willingness to adhere to the protocol.

Probably not a fit

Patients who do not respond to ultrasound modulation or who have underlying conditions that affect tremor could see no benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study enrolls twelve adults with essential tremor to receive six sessions of low intensity focused ultrasound targeting the thalamic Vim region over roughly two weeks. Outcomes include clinician-rated tremor scales, patient quality of life, and objective movement data collected before and after each session, with follow-ups at one and three months. MRI safety scans are done at baseline and after the final session to monitor any brain changes. The aim is to see if non-ablative ultrasound can safely affect tremor circuits and provide preliminary data for future controlled trials.

Why it matters

Potential benefit: If successful, participants might experience temporary tremor reduction and improved daily function.

How similar studies have gone: Prior non-ablative focused ultrasound approaches have shown safety signals in related movement disorders, with limited but encouraging tremor data.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Confirmed clinical diagnosis of ET
2. Isolated tremor syndrome, at least 3 years duration
3. Subjective complaint of tremor assessed and validated by physician
4. Must be willing to comply with the study protocol
5. English Proficiency
6. At least 18 years of age
7. At most 90 years of age

Exclusion Criteria:

1. Severe microvascular disease or structural brain lesions equivalent to Fazekas scale of 3 or higher in the periventicular or deep white matter.
2. Subjects on blood thinning medications (e.g. Eliquis)
3. Recent stroke (within the last 6 months)
4. Implanted electrodes (e.g. DBS) in brain
5. History of aneurysm
6. History of cranial trauma resulting in fracture or traumatic brain injury
7. Subjects who are unable to cooperate with the testing.
8. Subjects who lack capacity to consent
9. Subjects with severe cardiac disease, increased intracranial pressure, or using a transcutaneous electrical nerve stimulation (TENS) unit.
10. Severe cardiac disease will be defined as any of the following:

    i) History of myocardial infarction within the past 6 months ii) Diagnosis of congestive heart failure with NYHA Class III or IV symptoms iii) History of unstable angina, life-threatening arrhythmias, or use of an implantable cardioverter-defibrillator (ICD) iv) Uncontrolled hypertension (SBP \>180 mmHg or DBP \>110 mmHg) despite medication v) Any condition judged by the study physician to place the subject at increased risk from study participation
11. Subjects with implanted medical devices
12. Subjects with a history of seizure disorder.
13. Subjects with contraindications to enter MRI environment
14. Subjects with a history of substance abuse.
15. Subjects who are currently pregnant. This will be verified by a urine test prior to beginning the study.

Where it's running

  • UCLA Semel Institute for Neuroscience and Human Behavior
    Los Angeles, California, United States
    Recruiting

Study contacts

  • Principal investigator: William Zeiger, MD, PhD — University of California, Los Angeles
  • Study coordinator: Andrew Bishay
  • Email: andrewbishay@ucla.edu
  • Phone: 4243719869

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.